Cancer Immunology Immunotherapy

Article	Citations
Pembrolizumab and atezolizumab in triple-negative breast cancer	145
Chemotherapy: a double-edged sword in cancer treatment	101
An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma	101
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis	100
Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma	90
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC	84
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives	76
Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer	75
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma	71
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity	70
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway	67
Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)	63
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells	62
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer	61
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer	60
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy	57
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%	56
A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment	56
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer	52
Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma	48
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab	47
Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer	46
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disea	45
Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma	45
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial	43

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer	43
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma	43
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study	42
Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase	42
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis	42
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors	41
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors	40
Regulatory T cells promote glioma cell stemness through TGF-β–NF-κB–IL6–STAT3 signaling	40
Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome	40
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers	39
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes	38
Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site	37
TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer	36
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas	36
Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma	35
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer	35
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration	35
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas	34
CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer	34
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis	34
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab	33
Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors	33
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncol	33
Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis	33
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer	32
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China	32
Curdlan, zymosan and a yeast-derived β-glucan reshape tumor-associated macrophages into producers of inflammatory chemo-attractants	31
Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis	31
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors	31
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte	31
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients	31
Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials	31
Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models	30
IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma	30
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab	30
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment	30
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors	30
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma	30
Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status	29
Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer	29
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL	29
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer	28
Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer	28
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2	28
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors	28
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC	28
Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values	27
Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis	27
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma	27
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers	27

Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodi	27
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer	27
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells	27
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape	27
Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)	27
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression	26
Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions	26
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients	26
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy	26
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors	26
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1	26
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice	25
Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma	25
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer	25
Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer	25
Interleukin-12 as an in situ cancer vaccine component: a review	24
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies	24
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study	24
Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18	24
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies	24
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study o	24
Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors	24
T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer	24
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas	24
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience	23
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer	23
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC	23
Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment	23
Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment	23
LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway	23
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma	23
Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study	23
Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy	23
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer	23
Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TA	23
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR	22
Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC)	22
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway	22
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)	22
Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy	22
miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis	22
Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration	22
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia	21
Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10	21
Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations	21
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy	21
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients	21
Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis	21
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells	21
Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis	21
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient	21
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer	20
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy	20
The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma	20
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma	20
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer	20
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review	20
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors	20
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer	20
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide	20
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review	20
Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10	20
PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients	19
Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial	19
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports	19
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors	19
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma	19
Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy	19
Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer	19
Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab	19
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient	18
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature	18
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application	18
Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors	18
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study	18
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study	18
Exhaustion in tumor-infiltrating Mucosal-Associated Invariant T (MAIT) cells from colon cancer patients	18
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody	18
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment	18
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated he	18

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations	18
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma	18
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells	18
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma	18
Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma	18
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity	17
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab	17
Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma	17
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors	17
Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors	17
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	17
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study	17
Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma	17
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma	17
PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures	17
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors	17
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy	17
Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma	17
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis	17
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial	16
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21	16
CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma	16
TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma	16
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis	16
PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model	16
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment	16
In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes	16
Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas	16
A novel immune-related gene-based prognostic signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy	16
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade	16
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy	16
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody	16
Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer	16
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters	16
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model	16
CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma	16
Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature	16
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186	16
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma	15
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients	15
B7-H3 is spliced by SRSF3 in colorectal cancer	15
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer	15
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors	15
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer	15
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIM	15
TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells	15
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL	15
Evaluation of cytokines in the tumor microenvironment of lung cancer using bronchoalveolar lavage fluid analysis	15
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity	15
Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer	15
Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint	15
Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance	15
The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells	15
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma	14
Functional virus-specific memory T cells survey glioblastoma	14
Multi-antigen DNA vaccine delivered by polyethylenimine and Salmonella enterica in neuroblastoma mouse model	14
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model	14
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients	14
Varied functions of immune checkpoints during cancer metastasis	14
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung	14
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer	14
Are we ready to use TMB in breast cancer clinical practice?	14
Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program	14
Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes	14
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy	14
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used	14
Sex differences in the association between tumor growth and T cell response in a melanoma mouse model	14
Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions	14
Platelet-expressed immune checkpoint regulator GITRL in breast cancer	14
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma	14
Metabolomic profiling of tumor-infiltrating macrophages during tumor growth	14
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy	14
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2	14
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma	14
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes	14
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor	14
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma	14
Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody	14
CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy	14
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas	13
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial	13
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?	13
Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies	13
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect	13
A gene expression-based immune signature for lung adenocarcinoma prognosis	13
Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq	13
Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation	13
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses	13
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells	13
Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1	13
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease	13
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer	13
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody	13
A TLR4–TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cells	13
CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment	13